ChromaDex (CDXC) and Abeona Therapeutics (ABEO) Critical Analysis
ChromaDex (NASDAQ: CDXC) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.
Risk and Volatility
ChromaDex has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the S&P 500.
Institutional and Insider Ownership
6.8% of ChromaDex shares are held by institutional investors. Comparatively, 42.0% of Abeona Therapeutics shares are held by institutional investors. 11.6% of ChromaDex shares are held by insiders. Comparatively, 6.8% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares ChromaDex and Abeona Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ChromaDex||$26.81 million||11.86||-$2.92 million||($0.14)||-47.14|
|Abeona Therapeutics||$890,000.00||804.20||-$21.87 million||($0.66)||-23.18|
ChromaDex has higher revenue and earnings than Abeona Therapeutics. ChromaDex is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current ratings and price targets for ChromaDex and Abeona Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ChromaDex presently has a consensus price target of $7.00, suggesting a potential upside of 6.06%. Abeona Therapeutics has a consensus price target of $27.00, suggesting a potential upside of 76.47%. Given Abeona Therapeutics’ higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than ChromaDex.
This table compares ChromaDex and Abeona Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Abeona Therapeutics beats ChromaDex on 7 of the 12 factors compared between the two stocks.
ChromaDex Company Profile
Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.
Receive News & Ratings for ChromaDex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.